Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas

Bibliography

• Koç N, Ayas S, Uygur L. The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer. Gynecol Oncol 2014;134:486-91
   PubMed Web of Science ®Google Scholar
• Nik NN, Vang R, Shih IeM, et al. Origin and pathogenesis of pelvic (ovarian tubal and primary peritoneal) serous carcinoma. Annu Rev Pathol 2014;9:27-45
   PubMed Web of Science ®Google Scholar
• Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9
   PubMed Web of Science ®Google Scholar
• Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009;33:376-83
   PubMed Web of Science ®Google Scholar
• Shih IM, Kurman RJ. Ovarian tumorigenesis- a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-18
   PubMed Web of Science ®Google Scholar
• Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci 2011;3:625-34
   Google Scholar
• Ciardiello F, Tortora G. EGFR antagonist in cancer treatment. N Engl J Med 2008;358:1160-74
   PubMed Web of Science ®Google Scholar
• Lafky JM, Wilken JA, Baron AT, et al. Clinical implications of the Erb/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008;1785:232-65
   PubMed Web of Science ®Google Scholar
• Moyer CD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vadjos FF, et al. Insights into ErbB signaling from the structure of the ErbB2 – pertuzumab complex. Cancer Cell 2008;5:317-28
   Google Scholar
• Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11:5539-48
   PubMed Web of Science ®Google Scholar
• Posadas EM, Liel MS, Kiwitkowki V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109:1323-30
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009;3:138-50
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61
   PubMed Web of Science ®Google Scholar
• Vergote I. Novel therapies, including enzastaurin, in the treatment of ovarian cancer. Expert Opin Investig Drugs 2014;23:579-98
   PubMed Web of Science ®Google Scholar
• Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013;3:237
   PubMedGoogle Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly-ADP-rybose polymerase inhibitor olaparib in patients with BRCA1 and BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple negative breast cancer: a phase 2, multicentre, open-label, non-randomized study. Lancet Oncol 2011;12:852-61
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinsky J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal soxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372-9
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination of cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study. Lancet Oncol 2014;15:1207-14
   PubMed Web of Science ®Google Scholar
• Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-34
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-17
   PubMed Web of Science ®Google Scholar
• Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol 2014;133:362-9
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• Wei XW, Zhang ZR, Wei YQ. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment. Expert Opin Investig Drugs 2013;22:1181-92
   PubMed Web of Science ®Google Scholar
• Hall M, Goulrley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013;108:250-8
   PubMed Web of Science ®Google Scholar
• Klasa-Mazurkiewicz D, Jarzab M, Milczek T, et al. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 2008;62:31-40
   Google Scholar
• Siddiqui GK, Maclean AB, Elmasry K, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis 2011;14:155-61
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of Bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
   PubMed Web of Science ®Google Scholar
• Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-8
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302-8
   PubMed Web of Science ®Google Scholar
• Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics 2011;5:1-5
   PubMedGoogle Scholar
• Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics and antitumor activity of AMG386 a selective angiopoietin inhibitor in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-65
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30:362-71
   PubMed Web of Science ®Google Scholar
• Monk B, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomized, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15:799-808
   PubMed Web of Science ®Google Scholar
• Heckman CA, Holopainen T, Wirzenius M, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008;68:4758-62
   Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400
   PubMed Web of Science ®Google Scholar
• Ledermann J, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial [abstract 10]. 2013 European Cancer Congress; 13 September 2013; Amsterdam, Netherlands
   Google Scholar
• Friedlander M, Hancock KC, Rischin D. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32-7
   PubMed Web of Science ®Google Scholar
• duBois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32:3374-82
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-804
   PubMed Web of Science ®Google Scholar
• du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomized placebo-controlled CGIG/ENGOT – INTERGROUP phase III trial of standard frontline chemotherapy ± nintendanib for advanced ovarian cancer [abstract]. Int J Gynecol Cancer 2013;23:LBA1
   Google Scholar
• Annunziata CM, Walker AJ, Minasian L, et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010;16:664-72
   PubMed Web of Science ®Google Scholar
• Doff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol 2014;7:67-73
   PubMedGoogle Scholar
• Horsman MR, Sieman DW. Pathophysiologic effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39
   PubMed Web of Science ®Google Scholar
• Hall M, Gourley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013;108:250
   PubMed Web of Science ®Google Scholar
• Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum resistant ovarian cancer. Ann Oncol 2011;22:2036-41
   PubMed Web of Science ®Google Scholar
• Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
   PubMed Web of Science ®Google Scholar
• Peng DJ, Wang J, Zhou JY, et al. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010;394:600-5
   Web of Science ®Google Scholar
• Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;25:5853-7
   Google Scholar
• Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82
   PubMed Web of Science ®Google Scholar
• Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011;115:215-20
   Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
   PubMed Web of Science ®Google Scholar
• Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet 2013;29:394-402
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu P, Li H. Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors. Mol Med Rep 2013;7:1705-9
   Web of Science ®Google Scholar
• Dizon S, Damstrup L, Finkler NJ, et al. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer 2012;22:979-86
   PubMed Web of Science ®Google Scholar
• Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93
   PubMed Web of Science ®Google Scholar
• Miotti S, Bagnoli M, Ottone F, et al. Simultaneous activity of two different mechanism of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997;65:479-91
   PubMed Web of Science ®Google Scholar
• Walters CL, Arend RC, Armstrong DK, et al. Folate and folate receptor alpha antagonist mechanism of action in ovarian cancer. Gynecol Oncol 2013;131:493-8
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013;31:4400-6
   PubMed Web of Science ®Google Scholar
• Morris R, Joyrich RN, Naumann RW, et al. Phase II study of treatment of advanced ovarian cancer with folate-receptor.-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-ertafolide). Ann Oncol 2014;25:852-8
   PubMed Web of Science ®Google Scholar
• Marchi E, Mangone M, Zullo K, et al. Pralatrexate pharmacology and clinical development. Clin Cancer Res 2013;19:6657-61
   PubMed Web of Science ®Google Scholar
• Elstrand MB, Stavnes HT, Tropè CG, et al. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol 2012;43:529-35
   PubMed Web of Science ®Google Scholar
• Elpek GO, Karaveli S, Simsek T, et al. Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. APMIS 2003;111:523-30
   PubMed Web of Science ®Google Scholar
• Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical activity into clinical promise. Cancer Res 2014;74:1294-300
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9
   PubMed Web of Science ®Google Scholar
• Bräutigam K, Bauerschlag DO, Weigel MT, et al. Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. Transl Oncol 2009;2:164-73
   PubMed Web of Science ®Google Scholar
• Camidge DR, Gail Eckhardt S, Gore L, et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008;19:77-84
   PubMed Web of Science ®Google Scholar
• Vergote I, Amant F, Oskay-Oezcelik G, et al. Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study. Int J Gynecol Cancer 2009;19:1505-10
   PubMed Web of Science ®Google Scholar
• McNeish IA, Ledermann JA, Webber L, et al. A randomized, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol 2014;25:1988-95
   PubMed Web of Science ®Google Scholar
• Tse CW, Collins A, Oelher MK, et al. Antibody-based immunotherapy for ovarian cancer: where are we at? Ann Oncol 2014;25:322-31
   PubMed Web of Science ®Google Scholar
• Karkada M, Berinstein N, Mansour M, et al. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics 2014;8:27-38
   PubMedGoogle Scholar
• Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006;244:164-71
   PubMed Web of Science ®Google Scholar
• Won Kim D, Krishnamurthy V, Bines SD, et al. Trovax, a recombinant modified vaccinia Ankara virus encoding 5T4. Lesson learned and future development. Hum Vaccin 2010;6:784-91
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Quinn MA, Grant PT, et al. A phase 2, single-arm study of an autologus dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. J Immunother Cancer 2014;2:16
   PubMedGoogle Scholar
• Sebastian M. Review of catumaxomab in the treatment of malignant ascites. Cancer Manag Res 2010;2:283-6
   PubMedGoogle Scholar
• Heiss MM, Murawa P, Koralewski P. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-21
   PubMed Web of Science ®Google Scholar
• Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandani M, Ikeda T, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum resistant ovarian cancer. J Clin Oncol 2014;32(5s Suppl):abstract 5511
   Google Scholar
• Maleki Vareki S, Rytelewski M, Figueredo R, et al. Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 2014;5:2778-91
   PubMedGoogle Scholar
• Poveda A, Berton-Rigaud D, Ray-Coquard IR, et al. Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: results of a two-stage, controlled phase II study. J Clin Oncol 2014;32(5s Suppl):abstract 5505
   Google Scholar
• Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44
   PubMedGoogle Scholar
• Leone Roberti Maggiore U, Bellati F, Ruscito I, et al. Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther 2013;13:739-64
   PubMed Web of Science ®Google Scholar
• Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas 2014;77:128-36
   PubMed Web of Science ®Google Scholar
• Backen A, Renehan AG, Clamp AR. The combination of circulating ang1 and tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 2014;20:4549-58
   PubMed Web of Science ®Google Scholar
• Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 2014;32(5s Suppl):abstract 5502
   Google Scholar
• Pyragius CE, Fuller M, Ricciardelli C, et al. Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int J Mol Sci 2013;14:7742-56
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gonzalez-Martin A, García Y, et al. A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study. J Clin Oncol 2012;30(Suppl):abstract 5068
   Google Scholar
• Matulonis UM, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6
   PubMed Web of Science ®Google Scholar
• Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;29:69-75
   PubMed Web of Science ®Google Scholar